Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 6/20 | 0.76 |
| ▸ | FYN | P06241 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853937 | 0.96 | GPR52 (0.72) | GPR52FYNADORA3ADORA2BADORA2A | |
| SCHEMBL3206799 | 0.92 | GPR52 (0.78) | GPR52FYNADORA3ADORA2BADORA2A | |
| SCHEMBL3209129 | 0.89 | GPR52 (0.69) | GPR52FYNADORA3ADORA2B | |
| SCHEMBL1848382 | 0.89 | GPR52 (0.62) | GPR52FYNADORA3ADORA2BADORA2A | |
| SCHEMBL1850562 | 0.89 | GPR52 (0.72) | GPR52FYNADORA3ADORA2BADORA2A | |
| SCHEMBL1849152 | 0.89 | GPR52 (0.79) | GPR52FYNPTGER4NPC1GAA | |
| SCHEMBL1853932 | 0.89 | GPR52 (0.63) | GPR52ADORA3ADORA2BADORA2APTGER4 | |
| SCHEMBL3207391 | 0.88 | GPR52 (0.75) | GPR52FYNPTGER4 | |
| SCHEMBL3217594 | 0.88 | GPR52 (0.75) | GPR52FYNADORA3ADORA2BPTGER4 | |
| SCHEMBL3207056 | 0.86 | GPR52 (1.00) | GPR52PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885FYN 1500/4885ADORA3 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.